SLC5A2 and cardiovascular disorder: Hence, we started a systematic review of randomized controlled trials and observational trials to understand better the efficiency of SGLT2 inhibitors in providing protection from cardiovascular disorders and preventing renal adverse outcomes in individuals with T2DM.